Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List
18. November 2024 11:20 ET
|
SPR Therapeutics, Inc.
Ben Austin, CFO and COO of SPR® Therapeutics, Named
to Crain’s Cleveland Business 40 Under 40 List.
SPRINT® PNS Demonstrates Robust Results in Addressing Chronic Shoulder Pain
06. August 2024 09:00 ET
|
SPR Therapeutics, Inc.
A new real-world retrospective analysis of patients who received 60-day PNS for chronic shoulder pain has been published in Pain Management.
SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
15. Juli 2024 09:05 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics announced the presentation of five abstracts at the ASPN Annual Conference including four-year data on SPRINT PNS.
SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row
23. Juni 2024 10:00 ET
|
SPR Therapeutics, Inc.
Medical Device Leader SPR Therapeutics again named a Top Workplace in Northeast Ohio
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
11. Juni 2024 12:47 ET
|
SPR Therapeutics, Inc.
New Publication on Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
14. Mai 2024 18:33 ET
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
13. Mai 2024 14:16 ET
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
01. Februar 2024 09:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
16. Januar 2024 09:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics and the SPRINT PNS System will be featured prominently at the North American Neuromodulation Society Annual Meeting with 11 abstracts.
New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023
13. November 2023 09:05 ET
|
SPR Therapeutics, Inc.
Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain